Tirzepatide Overdose & Paralytic Ileus: Clinical Mechanisms

The Case: Tirzepatide Toxicity and Iatrogenic Paralysis

A 28-year-old female with bulimia nervosa presented to the emergency department with acute abdominal distension, vomiting, and complete absence of bowel sounds following an accidental tirzepatide overdose. Initial imaging revealed dilated small bowel loops with no mechanical obstruction—classic paralytic ileus. The patient had self-administered a multi-dose tirzepatide injection (estimated 15+ mg of a 2.5 mg/week formulation) in a single event. Resolution required 8 days of NPO status, nasogastric decompression, and supportive care.

This case illustrates a critical pharmacodynamic principle often overlooked in clinical practice: GLP-1 receptor agonists have a dose-response ceiling for GI benefit, beyond which they become GI toxins.

Mechanism: How GLP-1/GIP Overdose Paralyzes the Gut

Tirzepatide is a dual GLP-1/GIP receptor agonist. At therapeutic doses (2.5–15 mg weekly), it enhances postprandial insulin secretion and suppresses glucagon through receptor activation in pancreatic islets and brainstem nuclei. But the GI effects—delayed gastric emptying and reduced appetite—are dose-dependent and mediated through vagal signaling.

At physiologic doses: GLP-1 agonists modulate antral muscle contraction and trigger appropriate feedback satiety signals via the dorsal vagal complex.

At supraphysiologic doses: Sustained, saturating receptor occupancy causes tonic suppression of gastric and small-bowel motility. The vagal brake becomes stuck in the "closed" position. Acetylcholine-mediated peristalsis fails. Gastric accommodation persists indefinitely. Result: functional ileus without mechanical blockage.

The case patient's estimated bolus dose achieved plasma concentrations roughly 6–8× the peak level of a normal weekly injection. This overwhelmed negative feedback homeostasis in the enteric nervous system.

Why Baseline Testing Prevents This

Pre-tirzepatide screening should include:

• Comprehensive metabolic panel (CMP): Assess renal function (eGFR). GLP-1 agonists are renally cleared; impaired clearance increases half-life and plasma exposure.
• Fasting glucose and HbA1c: Establish baseline glycemic control to detect hypoglycemia risk if overdosed.
• Gastric motility history: Screen for prior gastroparesis, chronic nausea, or unexplained vomiting. These are contraindications to GLP-1 therapy.
• Psychiatric evaluation: Critical in bulimia nervosa. Eating disorder pathology may impair reliable self-administration and increase intentional overdose risk.

Clinical Pearls: Safe Tirzepatide Dosing

1. Titration is non-negotiable. Start at 2.5 mg weekly for 4 weeks. Increase by 2.5 mg increments only if GI tolerance permits.
2. Therapeutic ceiling exists. Above 15 mg/week, incremental weight loss benefit plateaus while adverse events (nausea, vomiting, GI dysmotility) escalate non-linearly.
3. Missed or delayed doses: Do not double-dose. The half-life is 5 days; a missed weekly injection requires only a single dose at the next scheduled time.
4. Patient education is liability control. All patients on GLP-1 agonists must understand: accidental overdose can cause life-threatening ileus requiring hospitalization.

Synergistic Supplements for GI Recovery

In the post-ileus recovery phase (after bowel function resumes), consider:

• Magnesium glycinate (300–400 mg daily): Restores smooth muscle excitability and acetylcholine sensitivity in intestinal myocytes. Avoid magnesium oxide (osmotic laxative effect).
• NAC (N-acetylcysteine, 1200–1800 mg daily): Reduces inflammatory cytokines (TNF-α, IL-6) in lamina propria following mucosal injury from prolonged ileus and nasogastric intubation.
• Omega-3 (2–3 g EPA+DHA daily): Anti-inflammatory; supports vagal tone recovery.
• Zinc (15–25 mg elemental daily, with food): Essential for intestinal barrier repair and mucosa regeneration.

The Bottom Line

Tirzepatide is a powerful and effective dual GLP-1/GIP agonist—when dosed correctly. Overdose is not merely an inconvenience; it is a pharmacological emergency capable of causing paralytic ileus, aspiration pneumonia, and multi-organ failure. The mechanism is not idiosyncratic but predictable: saturating receptor occupancy silences vagal-mediated GI motility.

Clinicians must:

1. Screen for contraindications (prior gastroparesis, eating disorders, renal impairment).
2. Enforce strict titration protocols.
3. Educate patients on accidental overdose risk.
4. Counsel on symptom recognition (severe bloating, persistent vomiting, absence of bowel movements >48 hours).

For patients with bulimia nervosa or other eating disorders, GLP-1 agonists require heightened supervision and may be contraindicated altogether.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.